Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2025Journal of Pharmaceutical And SciencesOpen Access

Molecular Docking Study of Luteolin and its Derivatives for Identifying Potential ER-α Inhibitors in Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFasha Jamil AtwonMDMuhammad Da’i

Discussion

Loading...

Member takes

Overview

Molecular docking reveals luteolin's superior binding affinity to ER-α in breast cancer, suggesting alternatives to endocrine therapies.

Key Points

  • Luteolin exhibited stronger binding affinity to ER-α compared to its glycosylated derivatives.
  • The binding affinity ranged from −7.2 to −8.0 kcal/mol for luteolin, whereas 4-hydroxytamoxifen was −8.9 to −9.4 kcal/mol.
  • Molecular docking analysis identified the structural basis for luteolin’s efficacy over glycosylated derivatives.
  • The research suggests improving luteolin’s bioavailability could enhance its potential in breast cancer therapy.

Cite This Study

Atwon et al. (2025) studied this question.

synapsesocial.com/papers/68d90a0f41e1c178a14f6b4ahttps://doi.org/10.36490/journal-jps.com.v8i3.1022
View Full Paper
Ask AI
Bookmark
Share